CO6150196A2 - Agentes que comprenden compuestos marcados con 18f y metodos relacionados - Google Patents

Agentes que comprenden compuestos marcados con 18f y metodos relacionados

Info

Publication number
CO6150196A2
CO6150196A2 CO09023386A CO09023386A CO6150196A2 CO 6150196 A2 CO6150196 A2 CO 6150196A2 CO 09023386 A CO09023386 A CO 09023386A CO 09023386 A CO09023386 A CO 09023386A CO 6150196 A2 CO6150196 A2 CO 6150196A2
Authority
CO
Colombia
Prior art keywords
group
nso2cf3
so2r5
branched
ortho
Prior art date
Application number
CO09023386A
Other languages
English (en)
Spanish (es)
Inventor
Lutz Lehmann
Ananth Srinivasan
Thomas Brumby
Detlef Sulzle
Timo Stellfeld
Keith Graham
Mylene Karramkam
Simon Ametamey
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090166A external-priority patent/EP1897885A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CO6150196A2 publication Critical patent/CO6150196A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CO09023386A 2006-09-08 2009-03-06 Agentes que comprenden compuestos marcados con 18f y metodos relacionados CO6150196A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06090166A EP1897885A1 (en) 2006-09-08 2006-09-08 Compounds and methods for F labelled agents
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules

Publications (1)

Publication Number Publication Date
CO6150196A2 true CO6150196A2 (es) 2010-04-20

Family

ID=39031005

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09023386A CO6150196A2 (es) 2006-09-08 2009-03-06 Agentes que comprenden compuestos marcados con 18f y metodos relacionados

Country Status (20)

Country Link
US (1) US8557776B2 (enExample)
EP (5) EP2279759A3 (enExample)
JP (2) JP5603074B2 (enExample)
KR (1) KR20090058553A (enExample)
AR (1) AR062726A1 (enExample)
AU (1) AU2007294124A1 (enExample)
BR (1) BRPI0716554A2 (enExample)
CA (2) CA2662449A1 (enExample)
CL (1) CL2007002620A1 (enExample)
CO (1) CO6150196A2 (enExample)
CR (1) CR10654A (enExample)
IL (4) IL197363A0 (enExample)
MA (1) MA30780B1 (enExample)
MX (1) MX2009002492A (enExample)
NO (1) NO20091428L (enExample)
PE (1) PE20080850A1 (enExample)
RU (1) RU2009112716A (enExample)
TN (1) TN2009000063A1 (enExample)
TW (1) TW200829277A (enExample)
WO (1) WO2008028688A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0716554A2 (pt) 2006-09-08 2013-09-24 Bayer Schering Pharma Ag compostos de mÉtodos para agentes rotulados de 18f
BRPI0721424A2 (pt) * 2007-03-01 2014-03-25 Bayer Schering Pharma Aktiengesellschaft Métodos de radiofluoração
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012094334A1 (en) * 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
EP2717985A4 (en) * 2011-06-09 2015-02-25 Ge Healthcare Ltd DEVICE AND METHOD FOR DISTILLATION
SMT202300035T1 (it) * 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
EP3129493B1 (en) 2014-04-09 2021-07-07 The Scripps Research Institute Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
WO2018152339A1 (en) * 2017-02-17 2018-08-23 Yale University Radiolabeled pharmaceuticals and methods of making and using same
TWI821192B (zh) 2017-07-11 2023-11-11 美商新索思股份有限公司 非天然核苷酸之導入及其方法
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
CN112930180A (zh) * 2018-04-20 2021-06-08 通用医疗公司 用于跨血脑屏障递送的乙酰化前药
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
CN113150065B (zh) * 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
US20240277876A1 (en) * 2021-05-20 2024-08-22 The Regents Of The University Of California Pet imaging tracers
WO2024204842A1 (ja) 2023-03-31 2024-10-03 日産化学株式会社 ピラゾール化合物及び有害生物防除剤

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084555A (en) * 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
WO1989002897A1 (en) * 1987-09-24 1989-04-06 The Administrators Of The Tulane Educational Fund Therapeutic peptides
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
JP2919889B2 (ja) * 1988-10-14 1999-07-19 アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド 治療用ペプチド
WO1990015153A1 (en) * 1989-06-02 1990-12-13 Georgetown University A method for the detection of anti-streptokinase antibodies
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5244883A (en) * 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
EP1042280A2 (en) 1997-12-24 2000-10-11 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6639076B1 (en) * 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
CA2375920A1 (en) * 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
US7115766B2 (en) * 2000-11-30 2006-10-03 Indiana University Research & Technology Corp. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
AU2003220441A1 (en) * 2002-04-09 2003-10-27 Eli Lilly And Company Dipeptidic growth hormone secretagogues
EP1527086B1 (en) * 2002-08-09 2008-01-09 Astellas Pharma Europe B.V. Compounds binding to p-selectin
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
US7342095B2 (en) * 2003-02-20 2008-03-11 University Of South Florida Peptidomimetic inhibitors of STAT activity and uses thereof
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2006083424A2 (en) 2004-12-28 2006-08-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
CA2617055A1 (en) 2005-07-29 2007-02-08 Bayer Healthcare Llc Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
US20080029548A1 (en) 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package
BRPI0716554A2 (pt) 2006-09-08 2013-09-24 Bayer Schering Pharma Ag compostos de mÉtodos para agentes rotulados de 18f

Also Published As

Publication number Publication date
US8557776B2 (en) 2013-10-15
CR10654A (es) 2009-04-14
EP2455105A3 (en) 2012-09-05
EP2279759A3 (en) 2013-04-17
JP5603074B2 (ja) 2014-10-08
CL2007002620A1 (es) 2008-05-30
RU2009112716A (ru) 2010-10-20
PE20080850A1 (es) 2008-09-02
TN2009000063A1 (en) 2010-08-19
BRPI0716554A2 (pt) 2013-09-24
NO20091428L (no) 2009-06-03
WO2008028688A2 (en) 2008-03-13
JP2010503618A (ja) 2010-02-04
US20080292548A1 (en) 2008-11-27
IL197363A0 (en) 2011-08-01
EP2455105A2 (en) 2012-05-23
CA2662449A1 (en) 2008-03-13
EP2063918A2 (en) 2009-06-03
AU2007294124A1 (en) 2008-03-13
JP5722966B2 (ja) 2015-05-27
MX2009002492A (es) 2009-08-28
EP2279759A2 (en) 2011-02-02
KR20090058553A (ko) 2009-06-09
IL211033A0 (en) 2011-04-28
EP2063918B1 (en) 2014-02-26
IL211527A0 (en) 2011-05-31
EP3056509A1 (en) 2016-08-17
TW200829277A (en) 2008-07-16
WO2008028688A3 (en) 2008-11-13
EP2289564A3 (en) 2012-11-14
MA30780B1 (fr) 2009-10-01
EP2455105B1 (en) 2016-02-17
AR062726A1 (es) 2008-11-26
IL211526A0 (en) 2011-05-31
JP2014028813A (ja) 2014-02-13
EP2289564A2 (en) 2011-03-02
CA2858907A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
CO6220836A2 (es) Compuestos activos biologicamnete marcados con fluoro-benzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo2,5-dioxo-pirrolidin-1-iloxi-benzoilo y trimetilamonio benzoilo
AR062726A1 (es) Composiciones que comprenden compuestos marcados con 18f y metodos relacionados
KR102502081B1 (ko) 발광 장치 및 화합물
WO2009057515A1 (ja) スルホン酸フェニル化合物、それを用いた非水電解液及びリチウム電池
MY183287A (en) Sulfonated internal olefin surfactant for enhanced oil recovery
ATE478087T1 (de) Polynukleotid, das ein phosphatmimetikum enthält
CO6241076A2 (es) Compuestos de benzamida y aplicaciones de los mismos
WO2009011447A3 (en) Iridium complex compounds, organic electroluminescent devices and uses thereof
UY33842A (es) ?pesticidas mesoiónicos?.
MY152959A (en) Sulfonated internal olefin surfactant for enchanced oil recovery
ES2189251T3 (es) Procedimiento de preparacion de diarilpiridinas utiles como inhibidores de cox-2'.
DOP2005000062A (es) Derivados de la 1-amino-ftalazina, su preparacion y su aplicación en terapeutica
AR074158A1 (es) Compuestos de bifenilos sustituidos y procedimiento de preparacion de dichos bifenilos sustituidos
PE20080999A1 (es) Azolilmetiloxiranos, su uso para combatir hongos fitopatogenos, asi como productos que los contienen
Li et al. Copper-mediated aerobic (phenylsulfonyl) difluoromethylation of arylboronic acids with difluoromethyl phenyl sulfone
RU2016114884A (ru) Отверждаемый способом фронтальный полимеризации строительный раствор на основе реактивной смолы и способ крепления стержневого анкера
Liu et al. Efficient synthesis of unsymmetrical S-(bromodifluoromethyl) diarylsulfonium salts for electrophilic bromodifluoromethylating reagents
WO2006136859A3 (en) Indoli zine derivatives and their use as crth2 antagonists
BR0214402A (pt) Processo para fabricação de éter de metil celulose
PL441714A1 (pl) Kompozycja ukorzeniacza roślin jednoliściennych oraz zastosowanie soli bis-amoniowych jako ukorzeniacze roślin jednoliściennych
AR093978A1 (es) Proceso para la preparacion de 4-amino-5-fluor-3-cloro-6-(sustituido)-picolinatos
HRP20080538T3 (en) Aryloxyethylamine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
RU2009147009A (ru) Органическое соединение серы и его применение для борьбы с вредными членистоногими
WO2019240884A3 (en) Compositions for chelating metals at low temperatures
CA2504912A1 (en) Heat transfer fluids for application over a broad range of temperatures